What is OLMA's market cap?

$647.04M, based on the Nov 4 close of $7.39.

Does Olema Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of OLMA is sold short?

15.7M shares, 24.8% of float, as of Oct 15, 2026.

What sector is OLMA in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · OLMAHealthcarePharmaceuticals

Olema Pharmaceuticals, Inc. Common Stock (OLMA)

$7.40+0.61%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$7.35▼ 12.71% in range

Nov 3, 2025Low $6.41 · High $35.83Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Olema Pharmaceuticals closed at $7.39 on Nov 4, up 0.61%, 79.4% below its 52-week closing high. Volume of 593.2K shares was 0.43× its 20-day average (below normal).

Split-adjusted performance: -6.6% over one month, -51.3% over six months, -12.2% over one year.

Short interest was 15.7M shares at the Oct 15 settlement, up 6.7% from the prior report (24.8% of float, 13.4 days to cover).

Market cap$647.0M87.5M shares

Revenue · quarter$0.00—

Diluted EPS$-0.61—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range6.41 – 35.83−79.4% from high

Volume593.2K0.43× 20-day avg

Volatility · 60d54.7%Annualised

Short % of float24.8%13.4 days to cover

Net cash$458.1MCash $461.1M

Next earnings—Not scheduled

Split-adjusted performance

1W −1.3%1M −6.6%3M −37.3%6M −51.3%YTD −70.4%1Y −12.2%3Y −44.2%5Y −72.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum23

Revenue growth—

Net margin—

Value (low P/E)—

Size65

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short15.7M+6.7% vs prior

Days to cover13.4Settled Oct 15

% of float24.8%

Short vol. 10d52.4%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
OLMAOlema Pharmaceuticals	$7.40	+0.61%	−51.3%	—	—	—	$647.0M
ZVRAZevra Therapeutics	$10.88	+6.04%	−3.3%	+44.9%	48.8%	8.4	$646.1M	Compare
IMMXImmix Biopharma	$7.79	+1.04%	−24.5%	—	—	—	$645.8M	Compare
DSGNDesign Therapeutics	$10.54	+1.93%	−27.6%	—	—	—	$659.6M	Compare
AVBPArriVent BioPharma	$12.87	−1.15%	−56.5%	—	—	—	$634.6M	Compare
LXRXLexicon Pharmaceuticals	$1.49	+2.05%	−6.9%	−97.6%	−4591.8%	—	$663.0M	Compare
GERNGeron	$1.04	+11.29%	−34.5%	+17.2%	−29.0%	—	$665.0M	Compare
APMDApnimed	$14.92	−0.93%	—	—	—	—	$621.1M	Compare
IRWDIronwood Pharmaceuticals, Inc. -	$3.72	+6.14%	−23.1%	+32.6%	45.4%	4.7	$613.9M	Compare

News about Olema Pharmaceuticals

All news →

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Sep 2, 2026Neutral Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate CancerGlobeNewswire Inc. · May 26, 2026▲ Positive Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual MeetingGlobeNewswire Inc. · May 21, 2026▲ Positive Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsGlobeNewswire Inc. · Mar 16, 2026▲ Positive Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMABenzinga · Mar 9, 2026▼ Negative

Quick answers

What does Olema Pharmaceuticals do?: Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers.
What is OLMA's market cap?: $647.04M, based on the Nov 4 close of $7.39.
Does Olema Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of OLMA is sold short?: 15.7M shares, 24.8% of float, as of Oct 15, 2026.
What sector is OLMA in?: Healthcare, in the Pharmaceuticals industry.

About Olema Pharmaceuticals

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

HQ: San Francisco, CA150 employeesListed Nov 19, 2020olema.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology